CPC C07K 16/2803 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); G01N 2333/70503 (2013.01)] | 14 Claims |
1. A method of treating a human subject for multiple myeloma with a therapeutic dose of anti-CD47 antibody hu5F9-G4, the method comprising:
(a) administering a priming dose of the hu5F9-G4 to the subject, where the priming dose is from about 0.5 to about 5 mg/kg, wherein the priming dose is administered to the human subject in an infusate with a concentration of from 0.05 mg/ml to 0.5 mg/ml hu5F9-G4 delivered over a period of at least 3 hours to reduce severity of hemagglutination; and
(b) administering a therapeutically effective dose of hu5F9-G4 to the subject wherein the therapeutically effective dose is 10-40 mg/kg,
wherein step (b) is after at least about 3 days after beginning step (a), wherein the priming dose primes the subject for administration of the therapeutically effective dose of anti-CD47 antibody such that the therapeutically effective dose does not result in a severe loss of red blood cells.
|